))
ACTINOGEN MEDICAL LTD (ACW) - Revolutionizing Mental Health Treatment: CEO Steve Gourlay on Breakthrough Xanamem Drug, Phase 2 Trial Success, and Future Implications
Manage episode 442926190 series 3570035
Andrew Musgrave에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Andrew Musgrave 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
What if controlling a single hormone in your brain could revolutionize the treatment of Alzheimer's and depression? On this episode of ASX Briefs, we're joined by Steve Gourlay, CEO of Actinogen Medical, a trailblazer in biotechnology, to unveil how their groundbreaking drug, Xanamem, could be a game-changer for mental health therapies. Steve takes us through Actinogen's fascinating journey from their 2014 merger with a University of Edinburgh startup to the promising Phase 2 depression trial results, where 167 patients showed significant improvement with minimal side effects.
Steve demystifies the complex science behind Xanamem, explaining how it targets brain cortisol, a hormone infamous for its role in stress and cognitive decline. With a deep dive into the biology of the brain, Steve enlightens us on how selectively reducing cortisol in regions like the hippocampus and frontal cortex can prevent the detrimental effects of chronic stress on nerve cells. This episode is a must-listen for anyone interested in the future of mental health treatment and how innovative therapies are set to change the landscape.
86 에피소드
공유
